DIAMEDICA THERAPEUTICS INC (DMAC) Fundamental Analysis & Valuation

NASDAQ:DMAC • CA25253X2077

7.95 USD
+0.16 (+2.05%)
At close: Mar 10, 2026
7.95 USD
0 (0%)
After Hours: 3/10/2026, 8:18:56 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This DMAC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to DMAC. DMAC was compared to 519 industry peers in the Biotechnology industry. DMAC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. DMAC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. DMAC Profitability Analysis

1.1 Basic Checks

  • In the past year DMAC has reported negative net income.
  • DMAC had a negative operating cash flow in the past year.
  • DMAC had negative earnings in each of the past 5 years.
  • DMAC had a negative operating cash flow in each of the past 5 years.
DMAC Yearly Net Income VS EBIT VS OCF VS FCFDMAC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • The Return On Assets of DMAC (-55.96%) is comparable to the rest of the industry.
  • The Return On Equity of DMAC (-61.85%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -55.96%
ROE -61.85%
ROIC N/A
ROA(3y)-42.76%
ROA(5y)-40.38%
ROE(3y)-46.99%
ROE(5y)-43.82%
ROIC(3y)N/A
ROIC(5y)N/A
DMAC Yearly ROA, ROE, ROICDMAC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

  • DMAC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DMAC Yearly Profit, Operating, Gross MarginsDMAC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. DMAC Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for DMAC has been increased compared to 1 year ago.
  • The number of shares outstanding for DMAC has been increased compared to 5 years ago.
  • DMAC has a worse debt/assets ratio than last year.
DMAC Yearly Shares OutstandingDMAC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
DMAC Yearly Total Debt VS Total AssetsDMAC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • DMAC has an Altman-Z score of 40.89. This indicates that DMAC is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of DMAC (40.89) is better than 94.22% of its industry peers.
  • A Debt/Equity ratio of 0.00 indicates that DMAC is not too dependend on debt financing.
  • DMAC has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 40.89
ROIC/WACCN/A
WACCN/A
DMAC Yearly LT Debt VS Equity VS FCFDMAC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • DMAC has a Current Ratio of 10.67. This indicates that DMAC is financially healthy and has no problem in meeting its short term obligations.
  • DMAC's Current ratio of 10.67 is amongst the best of the industry. DMAC outperforms 83.81% of its industry peers.
  • A Quick Ratio of 10.67 indicates that DMAC has no problem at all paying its short term obligations.
  • DMAC has a better Quick ratio (10.67) than 83.81% of its industry peers.
Industry RankSector Rank
Current Ratio 10.67
Quick Ratio 10.67
DMAC Yearly Current Assets VS Current LiabilitesDMAC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. DMAC Growth Analysis

3.1 Past

  • DMAC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -26.79%.
EPS 1Y (TTM)-26.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, DMAC will show a decrease in Earnings Per Share. The EPS will decrease by -2.64% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-16.28%
EPS Next 2Y-13.37%
EPS Next 3Y-14.37%
EPS Next 5Y-2.64%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DMAC Yearly Revenue VS EstimatesDMAC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
DMAC Yearly EPS VS EstimatesDMAC Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

0

4. DMAC Valuation Analysis

4.1 Price/Earnings Ratio

  • DMAC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DMAC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DMAC Price Earnings VS Forward Price EarningsDMAC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DMAC Per share dataDMAC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

  • A cheap valuation may be justified as DMAC's earnings are expected to decrease with -14.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.37%
EPS Next 3Y-14.37%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DMAC Dividend Analysis

5.1 Amount

  • DMAC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DMAC Fundamentals: All Metrics, Ratios and Statistics

DIAMEDICA THERAPEUTICS INC

NASDAQ:DMAC (3/10/2026, 8:18:56 PM)

After market: 7.95 0 (0%)

7.95

+0.16 (+2.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-31
Inst Owners19.79%
Inst Owner Change-7.3%
Ins Owners11.14%
Ins Owner Change1.93%
Market Cap414.04M
Revenue(TTM)N/A
Net Income(TTM)-31.93M
Analysts81.82
Price Target15.81 (98.87%)
Short Float %15.21%
Short Ratio17.67
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.48%
Min EPS beat(2)-4.17%
Max EPS beat(2)7.12%
EPS beat(4)2
Avg EPS beat(4)0.65%
Min EPS beat(4)-4.17%
Max EPS beat(4)7.12%
EPS beat(8)6
Avg EPS beat(8)5.09%
EPS beat(12)9
Avg EPS beat(12)3.21%
EPS beat(16)13
Avg EPS beat(16)10.78%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.02
P/tB 8.02
EV/EBITDA N/A
EPS(TTM)-0.71
EYN/A
EPS(NY)-0.77
Fwd EYN/A
FCF(TTM)-0.53
FCFYN/A
OCF(TTM)-0.53
OCFYN/A
SpS0
BVpS0.99
TBVpS0.99
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -55.96%
ROE -61.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.76%
ROA(5y)-40.38%
ROE(3y)-46.99%
ROE(5y)-43.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 95.35%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.67
Quick Ratio 10.67
Altman-Z 40.89
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)156.03%
Cap/Depr(5y)156.72%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-26.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.33%
EPS Next Y-16.28%
EPS Next 2Y-13.37%
EPS Next 3Y-14.37%
EPS Next 5Y-2.64%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-39.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-37.98%
EBIT Next 3Y-21.87%
EBIT Next 5YN/A
FCF growth 1Y-56.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-56.83%
OCF growth 3YN/A
OCF growth 5YN/A

DIAMEDICA THERAPEUTICS INC / DMAC FAQ

What is the ChartMill fundamental rating of DIAMEDICA THERAPEUTICS INC (DMAC) stock?

ChartMill assigns a fundamental rating of 2 / 10 to DMAC.


What is the valuation status of DIAMEDICA THERAPEUTICS INC (DMAC) stock?

ChartMill assigns a valuation rating of 0 / 10 to DIAMEDICA THERAPEUTICS INC (DMAC). This can be considered as Overvalued.


What is the profitability of DMAC stock?

DIAMEDICA THERAPEUTICS INC (DMAC) has a profitability rating of 1 / 10.


What is the expected EPS growth for DIAMEDICA THERAPEUTICS INC (DMAC) stock?

The Earnings per Share (EPS) of DIAMEDICA THERAPEUTICS INC (DMAC) is expected to decline by -16.28% in the next year.